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PURPOSE: To determine the eradication rate of an ultra-short treatment schedule for Helicobacter pylori infection in a
population with peptic ulcers, using omeprazole, secnidazole, and azithromycin in a once-daily dose for 3 days.
METHODS: Thirty patients with peptic ulcer diagnosed by upper endoscopy and for Helicobacter pylori infection by rapid
urease test and histologic examination received omeprazole 40 mg, secnidazole 1000 mg, and azithromycin 500 mg, administered
once daily for 3 days. A follow-up exam was performed 12 weeks after the end of the treatment. Patients who were negative for
Helicobacter pylori infection by rapid urease test and histologic examination were considered cured.
RESULTS: Patients were predominantly female, and the mean age was 50 years. Duodenal peptic ulcer was found in 73% of
the patients. Eradication was achieved in 9 of the 28 (32%) patients as determined from the follow-up endoscopic exam. The
eradication rate by intention to treat was 30%. Side effects were present in 3% of the patients, and compliance to treatment was total.
CONCLUSIONS: In spite of the low rate of side effects and good compliance, the eradication index was low. A possible
drawback of this therapy is that it reduces the efficacy of macrolide and nitroimidazole compounds in subsequent treatments.
DESCRIPTORS: Peptic Ulcer/Treatment. Helicobacter pylori/Eradication. Secnidazole/Therapeutic use. Azithromycin/
Therapeutic use. Omeprazole/Therapeutic use.
When the presence of Helicobacter
pylori is associated with peptic ulcer
disease, eradication of this bacterium
leads to the cure of the disease1, despite
the fact that an optimal antibiotic
schedule for its eradication has not yet
been found2. The complexity and ad-
verse effects of treatment and bacterial
resistance to the medications provide
different eradication rates, with several
treatment regimens used to date3-5. As
a general rule concerning bacteria that
are sensitive to antibiotics, a longer pe-
riod of treatment and different types of
medication promote a higher eradica-
tion rate for the chosen regimen6. How-
ever, this longer treatment regimen
may also bring more side effects and
result in lower compliance7.
Currently, therapy with 2 antibiotics
plus a proton pump inhibitor, one of
them clarithromycin and the other a
nitroimidazole compound, have resulted
in high eradication rates in several coun-
tries8-12. Concerning our patients, the
treatment with the proton pump inhibi-
tor, clarithromycin, and tinidazole eradi-
cated H. pylori infection in 75% of
those patients previously untreated13.
Many studies report good eradication
rates using a short-term treatment14-18.
The possibility of using a regimen in-
cluding macrolide and nitroimidazole
compounds, which have prolonged
plasma half-lives19-21, seemed to prom-
ise a short-term treatment with a high
efficacy. Therefore, the main objective
of this study was to assess the eradica-
tion rate of H. pylori achieved through
the combined use of omeprazole,
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azithromycin, and secnidazole with a
once-daily dose for 3 consecutive days
in a cohort with peptic ulcer.
PATIENTS AND METHODS
Thirty consecutive outpatients who
underwent upper digestive endoscopy
were invited to participate in the study.
 To be included in the study, pa-
tients had to have scar or active peptic
ulcer in the stomach or duodenum and
also had to be infected by H. pylori.
Patients were excluded from the
study if they: 1) were previously
treated for H. pylori infection, 2) had
a previous antibiotic treatment (within
the last 3 months), 3) were younger
than 16 years of age, 4) were pregnant
or lactating mothers, or 5) had previ-
ous gastric surgery or severe illness.
The Ethics and Science Committee
of our institution approved the study,
and all patients signed the written in-
formed consent statement.
The diagnose of the infection:
H. pylori infection was diagnosed
with the rapid urease test (RUT) and
from histologic examination (H & E
stain) of 2 gastric biopsy specimens
(antrum and body). The criteria for de-
termination of H. pylori eradication
were a negative RUT and negative his-
tology as determined from biopsy
specimens obtained during upper di-
gestive endoscopy performed 12 weeks
after the end of treatment.
The treatment:
The schedule of treatment consisted
of azithromycin 500 mg, secnidazole
1000 mg, and omeprazole 40 mg,
given once daily for 3 consecutive
days. At the end of treatment, the re-
maining pills were counted, side effects
were checked, and patients were re-
quested to discontinue the anti-ulcer
medication, except for the sympto-
matic use of antacids.
Statistical analysis was performed
using a SPSS v.8.0 (SPSS Inc., USA)
software package.
RESULTS
The baseline characteristics of the
population studied are shown on table
1. The predominant sex was female
(63%), and the percentage of duodenal
ulcer was nearly 7 times higher than
gastric ulcers. The mean age, close to
the median age, was 50 years. Tobacco
and non-steroidal anti-inflammatory
drug (NSAID) users, as well as alco-
holic patients, comprised a small
number of the patients. Migrants were
more numerous than the natives of the
city of São Paulo.
Treatment compliance was fully
successful (all patients took all doses
of the medication adequately), and
only 1 patient complained of a side ef-
fect (a light skin rash). Two patients
declined the follow-up endoscopic
exam. They were excluded from the
per protocol determination of the H.
pylori eradication rate. The H. pylori
eradication rate was 30% for all pa-
tients included in the study (intention–
to-treat rate) and 32% for the patients
who underwent endoscopic examina-
tion (per-protocol rate) (Table 2).
DISCUSSION
H. pylori eradication rates were
very low in our series, even consider-
ing that ours is a developing country
and that most patients were female
(who tend to harbor strains resistant to
secnidazole)22. A higher H .pylori
eradication rate was expected. It is well
known that the prevalence of resistant
bacteria varies from place to place in
the same country22,23, but in our center,
the prevalence of resistant bacteria was
not known. The rates of eradication
obtained were lower than the ones ob-
tained in a previous study carried out
with our patients with the use of
clarithromycin, tinidazole, and a pro-
ton pump inhibitor given twice a day
for 7 days13, where a 75% eradication
rate was achieved for those patients
who were previously untreated. Several
studies performed in Brazilian centers
with a triple-agent treatment regimen
of a week or less have also proved ef-
fective24-27.
Azithromycin is said to be a com-
pound similar to clarithromycin for the
eradication of H. pylori28,29. Unfortu-
nately this antibiotic is not always ap-
plicable, since it has a lower reliabil-
ity than clarithromycin for a 3-day
Table 1 - Clinical data.
Patients (n) 30
Age (years) Mean 51
Median 50








Table 2 - Helicobacter pylori eradication rates.
n / % Confidence Interval (95%)
Per protocol (n = 28) 9 / 32% 13% - 50%
Intention to treat (n = 30) 9 / 30% 12% - 47%
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treatment, alone or in combination with
other drugs 30-33. Secnidazole is a
nitroimidazole derivative and does not
differ from metronidazole. However, it
has a prolonged plasma half-life, and
for this reason, secnidazole is the first-
choice treatment for many diseases19.
For those patients from a disadvan-
taged cultural and social background, as
in our series, shorter and simpler sched-
ules result in better eradication rates.
Shorter, simpler treatment regimens lead
to higher compliance, lower cost, and
fewer side effects, which are important
issues for good outcomes34,35. From this
standpoint, the therapy used in this study
was close to the optimal treatment. All
patients took their medication properly,
and only one reported side effects.
The use of 2 antibiotics with an
even longer plasma half-life in a daily
dose, plus the ultra short-term use of
omeprazole (only 3 days), can jeopard-
ize the efficacy of the regimen.
In fact, the number of intakes and
in loco action of the antibiotics might
play an important role on H. pylori
eradication, since it is possible that the
ultra-short regimen reduces antibiotic
concentration on the gastric mucosa36.
Omeprazole induces bacterial growth,
and short-term use can prevent an op-
portunity for a more powerful antibac-
terial action37.
Increasing the number of days of
the regimen would make the treatment
similar to the regimen that uses the
proton pump inhibitor, tinidazole, and
clarithromycin twice a day for 7 days,
which would result in abandoning the
main attractive features of the regimen
reported here, that is, its simplicity,
shorter schedule, lower cost, and re-
duced side effects.
Nevertheless, the use of this treat-
ment regimen might reduce the effi-
cacy of macrolides and nitroimidazoles
in later treatments for those patients in
whom we were unable to eradicate H.
pylori infection38,39.
RESUMO RHCFAP/3062
SILVA FM e col. – Baixa eficácia de
um tratamento tríplice de curta
duração, em dose única diária, para
erradicação do Helicobacter pylori
em pacientes ulcerosos com Ome-
prazol, Azitromicina e Secnidazol.
Rev. Hosp. Clín. Fac. Med. S.
Paulo 57(1):9-14, 2002.
OBJETIVO: Testar a eficácia de
um esquema ultra-curto de erradicação
do H. pylori em uma população de
ulcerosos, usando Omeprazol,
Secnidazol e Azitromicina em dose
única diária por três dias.
PACIENTES E MÉTODOS:
Trinta doentes portadores de úlcera
péptica, documentada por exame
endoscópico e com infecção pelo H.
pylori confirmada pelo teste da urease
e exame histológico, foram tratados
com Omeprazol 40mg, Secnidazol
1000 mg e Azitromicina 500mg dados
em dose única diária por três dias. Em
controle endoscópico realizado 12 se-
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manas após o término do tratamento,
foram considerados curados da infec-
ção os pacientes que apresentaram o
teste da urease e exame histológico ne-
gativos para a bactéria.
RESULTADOS: As mulheres pre-
dominaram (63%), a idade média foi
de 50 anos e a úlcera duodenal foi
identificada em 73% dos pacientes.
Nos 28 doentes que realizaram o exa-
me de controle, a erradicação foi cons-
tatada em nove (32%). Por intenção de
tratamento o índice foi de 30%. A ade-
são ao tratamento foi total e houve um
baixo índice de efeitos adversos (3%).
CONCLUSÃO: O esquema apesar
de proporcionar alta adesão e poucos
efeitos adversos, apresenta baixa taxa de
erradicação, mesmo em se consideran-
do um país em desenvolvimento e apre-
senta como possível agravante compro-
meter a eficácia de outros macrolídeos
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